Clinical Trial Update: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for ADCT-301 in relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ADCT-301 (camidanlumab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2021-07-13